Dihydropyridine-based calcium antagonists (DHPs) are widely used to treat hypertension. We have previously shown that nifedipine, one of the most popular DHPs, blocks tumour necrosis factor-a (TNF-a)-induced monocyte chemoattractant protein-1 as well as vascular cell adhesion molecule-1 (VCAM-1) expression in endothelial cells by suppressing reactive oxygen species generation (ROS). The molecular mechanism is still to be elucidated, however, because endothelial cells do not possess voltage-operated Ltype calcium channels. The aim of this study was to determine in TNF-a-exposed human umbilical vein endothelial cells (HUVECs) whether and how Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium antagonistic properties, may suppress VCAM-1 expression, a key molecule which mediates the adhesion of monocytes to vasculature in the early stages of atherosclerosis. In HUVECs, 10 ng/ml TNF-a for 4 h stimulated ROS generation and subsequently upregulated VCAM-1 mRNA levels, both of which were dose-dependently blocked by Bay w 9798. The results demonstrated that Bay w 9798 inhibited VCAM-1 expression in TNF-a-exposed cells by suppressing ROS generation. They suggest that the antiinflammatory and anti-oxidative properties of nifedipine and Bay w 9798 may be ascribed to the dihydropyridine structure, which is common to both molecules and has no calcium antagonistic ability.
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Introduction
There is a growing body of evidence to show that atherosclerosis is intrinsically an inflammatory disease. 1 Indeed, the classic pro-inflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin-1, induce pro-thrombotic and proinflammatory reactions in endothelial cells, and are thus involved in the pathogenesis of endothelial dysfunction and atherosclerosis. 2,3 Upon exposure to these cytokines endothelial cells have been reported to undergo profound functional changes, including expression of vascular cell adhesion molecule-1 (VCAM-1), a key molecule that mediates leucocyte adhesion to vasculatures, an initial step in atherosclerosis. 4, 5 Dihydropyridine-based calcium antagonists (DHPs) are widely used for the treatment of patients with hypertension. 6 We have previously shown that nifedipine, one of the most popular DHPs, blocks TNF-α-induced monocyte chemoattractant protein-1 as well as VCAM-1 expression in endothelial cells by suppressing reactive oxygen species (ROS) generation. 7, 8 In vitro findings suggest an anti-inflammatory pleiotropic effect of nifedipine on atherosclerosis. 6 However, the underlying molecular mechanism for this effect is still to be elucidated, because endothelial cells do not possess voltageoperated L-type calcium channels. 9 These observations led us to the hypothesis that nifedipine could inhibit TNF-α-elicited endothelial cell activation through its unique anti-oxidative properties. In this study, therefore, we have examined whether and how Bay w 9798, a dihydropyridine that is structurally related to nifedipine with no calcium antagonistic properties, may suppress the expression of VCAM-1 in human umbilical vein endothelial cells (HUVECs).
Materials and methods

MATERIALS
Bay w 9798 was generously provided by Bayer Pharma (Wuppertal, Germany). TNFα was purchased from Sigma (St Louis, MO, USA). GeneAmp ® RNA PCR Core Kit was from Applied Biosystems (Branchburg, NJ, USA).
CELLS
The HUVECs were cultured in endothelial basal medium supplemented with 2% fetal bovine serum, 0.4% bovine brain extracts, 10 ng/ml human epidermal growth factor and 1 µg/ml hydrocortisone according to the supplier's instructions (Clonetics Corp., San Diego, CA, USA). TNF-α treatment was carried out in a medium lacking epidermal growth factor and hydrocortisone.
DIHYDROETHIDIUM STAINING
Endothelial cells were treated with 10 ng/ml TNF-α in the presence or absence of 1 or 10 µM Bay w 9798 for 4 h. The cells were then incubated with phenol red free Dulbecco's Modified Eagle Medium containing 3 µM dihydroethidium (DHE) (Molecular Probes Inc., Eugene, OR, USA). After 30 min, the cells were imaged under a laser scanning confocal microscope.
The fluorescent intensity of DHE staining for each sample was analysed by microcomputer-assisted NIH Image, version 1.62 (National Institutes of Health, Bethesda, MD, USA).
PRIMERS AND PROBES
Sequences of the sense and antisense primers for the detection of human VCAM-1 mRNA were 5´-TTCCTAGCGTGTACCCCCTTGACC-3´ and 5´-CAGAAAGAGGCTGTAGCTCCC CGT-3´. 8 The primers used for human β-actin mRNA detection were the same as described previously. 10 T Matsui, S Yamagishi, K Nakamura et al.
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SEMI-QUANTITATIVE RT-PCR
Poly(A) + RNAs were isolated from HUVECs treated with or without 10 ng/ml TNF-α in the presence or absence of 1 or 10 µM Bay w 9798 for 4 h, and were analysed by reverse transcription polymerase chain reaction (RT-PCR) as described previously. 10 The amount of poly(A) + RNA templates (30 ng) and cycle numbers for amplification (33 cycles for the VCAM-1 gene and 24 cycles for the β-actin gene) were chosen in quantitative ranges at which the reactions proceeded linearly; these had been determined by plotting signal intensities as functions of the template amounts and cycle numbers. 8
STATISTICAL ANALYSIS
All values were presented as the mean ± SE.
One-way analysis of variance (ANOVA), followed by the Scheffe F test, were performed to compare the means for each group. A P-value < 0.05 was considered to be statistically significant.
Results
The effects of Bay w 9798 on ROS generation in TNF-α-exposed HUVECs were investigated using DHE staining because DHE is taken up by endothelial cells and converted to the fluorescent product, ethidium, in the presence of superoxide. 11 As shown in Fig. 1 , TNF-α at a concentration of 10 ng/ml significantly increased fluorescence intensity compared with the control (P < 0.05). Bay w 9798 dose-dependently inhibited the increase in fluorescence intensity in TNF-α- TNF-α TNF-α + 1 µM BAY TNF-α + 10 µM BAY exposed HUVECs (P < 0.05 for 10 µM Bay w 9798). Superoxide generation in HUVECs was not affected by 10 µM Bay w 9798 alone (data not shown). The effects of Bay w 9798 on VCAM-1 gene expression in TNF-α-exposed HUVECs are shown in Fig. 2 . TNF-α significantly increased mRNA VCAM-1 levels compared with the control (P < 0.01). Bay w 9798 dosedependently suppressed mRNA VCAM-1 levels compared with TNF-α alone (P < 0.05 and P < 0.01 for 1 and 10 µM Bay w 9798, respectively). VCAM-1 mRNA levels in HUVECs were not affected by 10 µM Bay w 9798 alone (data not shown).
Discussion
An early phase of atherosclerosis involves the recruitment and firm adhesion of inflammatory cells to endothelial cells, 12 a process that is predominantly mediated by cellular adhesion molecules. 13 Indeed, arterial endothelium overlying atherosclerotic lesionprone areas expresses numerous adhesion molecules, such as P-selectin, intracellular adhesion molecule-1 and VCAM-1. 14 Among them, VCAM-1, a cytokine-inducible adhesion molecule that belongs to the immunoglobulin gene superfamily, is specially upregulated in arterial endothelial cells at the lesion-prone areas in hypercholesterolaemic animal models. 14 Furthermore, in apolipoprotein E null or low-density lipoprotein receptor null backgrounds, VCAM-1 domain 4 deficient mice have been shown to have a large reduction in early form cell lesions, thereby suggesting a major role of VCAM-1 in the initiation of atherosclerosis. 15, 16 
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The present study has demonstrated for the first time that Bay w 9798, a dihydropyridine that is structurally related to nifedipine with no calcium antagonistic properties, inhibits TNF-α-induced VCAM-1 gene induction in HUVECs. This has extended our previous findings that showed nifedipine to inhibit VCAM-1 expression and subsequent MOLT-3 human T cell adhesion to endothelial cells in TNF-α-exposed HUVECs. 8 Taking our previous and present finding together suggests that the antiinflammatory and anti-oxidative properties of nifedipine and Bay w 9798 may be ascribed to the common dihydropyridine structure of both molecules (Fig. 3) , which has no calcium antagonistic ability. The presence of an unsubstituted nitrogen in the dihydropyridine is indispensable for a calcium antagonistic effect, whereas substitution of the hydrogen at the nitrogen (H-N=residue), e.g. by a methyl group or oxygen, leads to a loss of calcium antagonism, although anti-oxidative properties are retained. The increased release and production of ROS by cells in the vascular wall has been considered an initial event in the pathogenesis of atherosclerosis. 17, 18 Endothelial VCAM-1 gene transcription and expression are also regulated through an oxidative stress-sensitive mechanism. 19 The present study showed that Bay w 9798 blocks TNF-α-induced ROS generation in HUVECs, suggesting that Bay w 9798 may suppress TNF-α-induced VCAM-1 expression, at least in part, through its anti-oxidative properties.
